Skip to main content
. 2016 Dec 21;8(4):6319–6329. doi: 10.18632/oncotarget.14062

Figure 1. Inhibition of Class II HDACs has no impact on the expression of BRCA1, CHK1, and RAD51 in AML cells.

Figure 1

(A and B) THP-1 and OCI-AML3 cells were treated with MC1568 for 48 h, and then whole cell lysates were subjected to Western blotting and probed with the indicated antibodies. (C amd D) THP-1 and OCI-AML3 cells were treated with Tubastatin A for 48 h, and then whole cell lysates were subjected to Western blotting and probed with the indicated antibodies.